Keros Therapeutics Inc (KROS)

$13.47 -0.27 (-1.97%)
Market Cap 558.05M
Revenue (ttm) 3.55M
Net Income (ttm) -187.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,277.47%
Debt to Equity Ratio 0.00
Volume 537,900
Avg Vol 1,100,422
Day's Range N/A - N/A
Shares Out 40.62M
Stochastic %K 16%
Beta 1.32
Analysts Strong Sell
Price Target $27.33

Latest News on KROS

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 12, 2025, 12:11 PM EDT - 2 days ago

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

May 12, 2025, 8:00 AM EDT - 2 days ago

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Keros Reinforces Commitment to Maximizing Stockholder Value

May 8, 2025, 5:31 PM EDT - 5 days ago

Keros Reinforces Commitment to Maximizing Stockholder Value

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

May 8, 2025, 2:10 PM EDT - 5 days ago

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 7 days ago

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Apr 10, 2025, 1:51 PM EDT - 4 weeks ago

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Apr 10, 2025, 12:12 PM EDT - 4 weeks ago

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Keros Therapeutics adopts 'poison pill' plan

Apr 10, 2025, 6:10 AM EDT - 4 weeks ago

Keros Therapeutics adopts 'poison pill' plan

Keros Therapeutics Announces Review of Strategic Alternatives

Apr 10, 2025, 6:00 AM EDT - 4 weeks ago

Keros Therapeutics Announces Review of Strategic Alternatives

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Mar 31, 2025, 6:00 AM EDT - 6 weeks ago

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Feb 28, 2025, 5:00 PM EST - 2 months ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:01 PM EST - 2 months ago

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Jan 31, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 30, 2025, 10:00 AM EST - 3 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 8:00 AM EST - 3 months ago

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Jan 29, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Jan 28, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Jan 27, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Jan 26, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 24, 2025, 10:00 AM EST - 3 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Jan 23, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 21, 2025, 10:00 AM EST - 4 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation

Jan 20, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation

Jan 19, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out

Jan 17, 2025, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Reach Out

Jan 16, 2025, 2:30 PM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Reach Out

Keros halts hypertension treatment trial on safety issues

Jan 15, 2025, 6:41 AM EST - 4 months ago

Keros halts hypertension treatment trial on safety issues

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

Jan 15, 2025, 6:30 AM EST - 4 months ago

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial